Sumitomo Dainippon Pharma Co Ltd's Fiscal Year is From April To March - All Figures are in Percent.
The item "Return-On-Equity" stands at 79.61 percent as of 09/30/2025, the highest value at least since 06/30/2022, the period currently displayed.
As of the end of Sumitomo Dainippon Pharma Co Ltd's second quarter, the item "Return On Equity" stands at 79.61 Percent. This represents an increase of 67.53 percentage points compared to it's value at the end of it's first quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 223.91 compared to the value the year prior.
The Serie's long term average value is -29.08 percent. It's latest available value, on 09/30/2025, is 108.69 higher, compared to it's long term average value.
The Serie's change from it's minimum value, on 09/30/2024, to it's latest available value, on 09/30/2025, is +223.91 .
The Serie's change in percentage points from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Return On Equity | 905,699,262,464.00 |
![]() | Johnson & Johnson - Return On Equity | 486,508,953,600.00 |
![]() | AbbVie Inc - Return On Equity | 399,570,305,024.00 |
![]() | Roche Holding AG - Return On Equity | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Return On Equity | 280,205,508,085.11 |